PanGen Biotech Inc (222110) — Cash Flow-to-Debt Ratio
PanGen Biotech Inc (222110) has a Cash Flow-to-Debt Ratio of -1.34x as of September 2025, meaning its operating cash flow of ₩-3.66 Billion could theoretically repay -1% of its total liabilities (₩2.74 Billion) in one year. See PanGen Biotech Inc (222110) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PanGen Biotech Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for PanGen Biotech Inc across 11 annual periods. For the full cash flow conversion analysis, see PanGen Biotech Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for PanGen Biotech Inc (2014–2024)
Year-by-year debt coverage analysis for PanGen Biotech Inc. Check 222110 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.53x | ₩2.99 Billion | ₩5.64 Billion | ▲ +225.6% |
| 2023 | -0.42x | ₩-3.45 Billion | ₩8.18 Billion | ▲ +58.4% |
| 2022 | -1.01x | ₩-3.50 Billion | ₩3.45 Billion | ▼ -576.6% |
| 2021 | -0.15x | ₩-3.32 Billion | ₩22.18 Billion | ▲ +29.2% |
| 2020 | -0.21x | ₩-4.68 Billion | ₩22.10 Billion | ▼ -19.5% |
| 2019 | -0.18x | ₩-3.66 Billion | ₩20.66 Billion | ▲ +41.0% |
| 2018 | -0.30x | ₩-5.61 Billion | ₩18.67 Billion | ▼ -95.7% |
| 2017 | -0.15x | ₩-657.84 Million | ₩4.28 Billion | ▲ +92.6% |
| 2016 | -2.08x | ₩-4.35 Billion | ₩2.09 Billion | ▼ -1107.5% |
| 2015 | -0.17x | ₩-1.61 Billion | ₩9.34 Billion | ▲ +20.6% |
| 2014 | -0.22x | ₩-1.34 Billion | ₩6.18 Billion | — |